Chart: Inside JUPITER's Realm: A Closer Look At The Trial Results
AstraZenenca's JUPITER study pushes the boundaries of the statin class to a new level. The latest large-scale outcomes trial for the statin class, using AstraZenenca's Crestor (rosuvastatin), explores use in a population that has healthy LDL cholesterol levels but with high levels of an inflammation biomarker that predicts future cardiovascular events: high-sensitivity C-reactive protein.
You may also be interested in...
JPMorgan raises global sales estimate but cautions that AstraZeneca has under-invested in the statin.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials